Farmas USA

Eleuterio,,,jejeje disfrutas como un chaval de 15 años,,,,,,enhorabuena.

AQXP,,yo las compre a 1,56 y las vendi a 3 y pico,,,,lince para comprar ,novato para vender.

Buenas tardes, me acabo de incorporar.
Mi más sinceras felicitaciones a Eleuterio y Templarium por esos pluses y echarle los huevos que yo no tuve.

ATNM

Veo que ha llegado a 2,72 y yo fuera. Es que no se puede perder un minuto con estas pájaras.

Actinium Successfully Labels Antibody with Actinium-225 For Next Entry into Pipeline
Robustness of Actinium's Technology Platform Further Validated by New Pipeline Addition
Actinium Pharmaceuticals

NEW YORK, NY--(Marketwired - August 10, 2015) - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) successfully completed foundational phases of development of an antibody construct labeled with actinium-225 using the Company's novel proprietary APIT (Alpha Particle Immunotherapy Technology) platform. This new pipeline entry further validates the robustness of Actinium's platform technology. The labeled antibody has the potential to be broadly used in the field of hematology/oncology. Quality control testing of the new construct has confirmed that the product meets or exceeds all specifications related to biological integrity and properties of the labeled antibody. Early animal work has confirmed the biological properties of this new antibody drug conjugate (ADC).

Based on the successful outcome of this first phase in this new development program, collaborating parties are continuing preclinical development of the product leading to clinical trials. The Company is further evaluating biological effectiveness in appropriate animal models and also validating the clinical and market opportunity applicable to this product candidate. Assuming that the clinical and market potential of this antibody construct are confirmed, the Company expects to unveil the development plan and timing for the latest pipeline entry in the fourth quarter of 2015.

Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post surgery. "These initial results confirm that we have a very robust technology that is well protected on all sides with appropriate intellectual property," said Kaushik J. Dave, Actinium's President and CEO. "We can now continue moving forward with further development and evaluation of this latest product candidate which expands our pipeline."

About Actinium-225

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.

Cargadas otras pocas NVAX a 11.

AQXP

Enhorabuena. No está nada mal, buenos profits. Todos hemos pasado por ello, vender con buenas ganancias sin adivinar que aún venían mejores.... aplicamos eso de que el ultimo duro que se lo gane otro.....
S2

XOMA
Dando una alegría. A ver si llega al dólar.
Alguien sabe si es mañana al cierre la Conference call del CEO?

AQXP

Comprado otro lote a 37 dólares...

si rompe el$ compro una serie entera de loteria.